Stock search

Ticker or company name

Viatris

VTRS · NASDAQ · Pharmaceuticals

$20,74Down −0,08 (−0,38%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$21,9 bn
Div. yield
5,1%
Year to date
+67,2%
52 weeks: $10,15$21,20

Ratio score

36/100
Ratio would not consider buying

based on 7 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

2 ✓ · 1 — · 4 ✕ · 3 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTMn/a33,841,8
Forward P/E7,1—12,4
PEGn/a—3,3
P/S1,60,83,4
EV/EBITDA12,69,724,0
P/FCF11,8—14,0
P/B1,70,78,1

Industry median — across 6 profitable companies in “Pharmaceuticals” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 18 analysts

Buy
12
Hold
5
Sell
1

Beat the EPS forecast in 4 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20260,650,71Up +9,3%
Q2 20260,610,69Up +12,6%
Q1 20260,510,59Up +15,2%
Q4 20250,540,57Up +4,8%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue3,73 bn3,75 bn3,51 bn3,69 bn3,75 bn3,57 bn3,24 bn3,52 bn3,74 bn3,79 bn3,65 bn3,83 bn
EPS−0,28−0,100,15−0,30−0,110,00−2,55−0,430,08−0,270,09−0,63
Margin————————————
FCF814 m329 m348 m619 m658 m167 m493 m342 m750 m320 m565 m314 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $1,09 m.

NameAmountSharesPrice
campbell paul25 Jun 2026 · sale$809 78450 076$16,17
campbell paul23 Mar 2026 · sale$283 53921 350$13,28

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Pharmaceuticals
Exchange
NASDAQ
Country
US
IPO date
1 Feb 1973

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
ZTSZoetis$84,3975would consider12,4+1,2%26,1%
BMYBristol Myers Squibb$62,9381would consider14,0+4,2%18,5%
PFEPfizer$28,8644would watch40,8+1,3%6,3%
MRKMerck & Co.$144,4638would not consider148,5+4,9%3,6%
JNJJohnson & Johnson$282,5544would watch42,9+7,8%16,2%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.